More is not better: PARP dose can be safely reduced for people with ovarian cancer

https://www.facingourrisk.org/XRAY/PARP-dose-reduction-for-ovarian-cancer

Full article: https://www.annalsofoncology.org/article/S0923-7534(22)00338-6/fulltext

Maintenance therapy with a PARP inhibitor is now the standard of care for many people with advanced or recurrent ovarian cancer. However, PARP inhibitors may have significant side effects. This study shows that reducing the dose of a PARP inhibitor does not affect survival. (Posted 11/8/22)

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Is olaparib maintenance therapy an option for me?
What side effects of olaparib therapy could lead to the need to reduce the dose or interrupt treatment?
How will the side effects of olaparib therapy be monitored and managed?
How will I know whether I should take my daily olaparib dose or not?

Open Clinical Trials

The following are studies looking at PARP inhibitors and similar agents for treating people with ovarian cancer.

NCT03579316: Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. This studies how well adavosertib with or without olaparib work in patients with ovarian cancer that has come back (recurrent).

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.